NYSE:JNJ - Johnson & Johnson Stock Price, Price Target & More

$126.66 -0.89 (-0.70 %)
(As of 04/23/2018 07:37 AM ET)
Previous Close$127.55
Today's Range$126.17 - $128.30
52-Week Range$121.54 - $148.32
Volume7.74 million shs
Average Volume7.94 million shs
Market Capitalization$339.82 billion
P/E Ratio17.35
Dividend Yield2.63%
Beta0.74

About Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson logoJohnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads under the STAYFREE and CAREFREE brands, and tampons under the o.b. brand; wound care products comprising adhesive bandages under the BAND-AID brand and first aid products under the NEOSPORIN brand. The company's Pharmaceutical segment offers various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, cardiovascular and metabolic, and pulmonary hypertension diseases. Its Medical Devices segment provides orthopedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; diabetes care products that include blood glucose monitoring; and vision care products, such as disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery. The company markets its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.

Receive JNJ News and Ratings via Email

Sign-up to receive the latest news and ratings for JNJ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:JNJ
CUSIP47816010
Phone732-524-0400

Debt

Debt-to-Equity Ratio0.51%
Current Ratio1.41%
Quick Ratio1.12%

Price-To-Earnings

Trailing P/E Ratio17.35
Forward P/E Ratio15.58
P/E Growth1.94

Sales & Book Value

Annual Sales$76.45 billion
Price / Sales4.44
Cash Flow$9.5592 per share
Price / Cash13.25
Book Value$22.39 per share
Price / Book5.66

Profitability

EPS (Most Recent Fiscal Year)$7.30
Net Income$1.30 billion
Net Margins1.58%
Return on Equity30.05%
Return on Assets13.29%

Miscellaneous

Employees134,000
Outstanding Shares2,682,900,000

How to Become a New Pot Stock Millionaire

Johnson & Johnson (NYSE:JNJ) Frequently Asked Questions

What is Johnson & Johnson's stock symbol?

Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."

How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?

Johnson & Johnson declared a quarterly dividend on Tuesday, January 2nd. Shareholders of record on Tuesday, February 27th will be given a dividend of $0.84 per share on Tuesday, March 13th. This represents a $3.36 annualized dividend and a yield of 2.65%. The ex-dividend date is Monday, February 26th. View Johnson & Johnson's Dividend History.

How were Johnson & Johnson's earnings last quarter?

Johnson & Johnson (NYSE:JNJ) posted its earnings results on Tuesday, April, 17th. The company reported $2.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.00 by $0.06. The business had revenue of $20.01 billion for the quarter, compared to analysts' expectations of $19.50 billion. Johnson & Johnson had a return on equity of 30.05% and a net margin of 1.58%. The firm's revenue for the quarter was up 12.6% compared to the same quarter last year. During the same quarter last year, the firm posted $1.83 EPS. View Johnson & Johnson's Earnings History.

When is Johnson & Johnson's next earnings date?

Johnson & Johnson is scheduled to release their next quarterly earnings announcement on Tuesday, July, 17th 2018. View Earnings Estimates for Johnson & Johnson.

What guidance has Johnson & Johnson issued on next quarter's earnings?

Johnson & Johnson updated its FY18 earnings guidance on Tuesday, April, 17th. The company provided EPS guidance of $8.00-8.20 for the period, compared to the Thomson Reuters consensus estimate of $8.10. The company issued revenue guidance of $81.0-81.8 billion, compared to the consensus revenue estimate of $81.18 billion.

What price target have analysts set for JNJ?

20 analysts have issued 1-year price objectives for Johnson & Johnson's shares. Their predictions range from $110.00 to $165.00. On average, they expect Johnson & Johnson's stock price to reach $143.7222 in the next twelve months. View Analyst Ratings for Johnson & Johnson.

What are Wall Street analysts saying about Johnson & Johnson stock?

Here are some recent quotes from research analysts about Johnson & Johnson stock:
  • 1. According to Zacks Investment Research, "J&J’s sales growth accelerated in the second half of 2017 backed by higher sales in the Pharmaceutical segment and improving performance in Medical Devices. Though quite a few key products in J&J’s portfolio like Remicade and Concerta are facing generic competition, we believe that new products in all segments, label expansion of drugs like Imbruvica and Darzalex and contribution from recent acquisitions - mainly Actelion – can support top-line growth. Meanwhile, share buybacks and the restructuring initiative should provide bottom-line support. However, headwinds like generics, pricing pressure and soft global market conditions remain. Sluggish growth in the Consumer segment is also a concern. J&J’s shares have underformed the industry in this year so far. Estimates have risen slightly ahead of Q1 results. J&J has a positive record of earnings surprises in the recent quarters." (4/16/2018)
  • 2. BTIG Research analysts commented, "Present – Starting to Outweigh Macro Tailwinds On Tuesday before market-open, JNJ reported 4Q17 financial results. In- line with our forecasting for the Pharma segment, the Actelion portfolio has begun to significantly disappoint expectations, Remicade erosion is accelerating, and mainstay franchises such as Imbruvica are beginning to moderate growth. The major discussion point we have had with investors is whether our negative Pharma thesis can trump the positive macro factors. We continue to think so, despite tailwinds such as tax reform helping the stock and overall stock market during 2H2017. At the end of the day, Pharma drives over 50% of total profit generation for the company. We reiterate our Sell rating and $110 PT.   We forecast 1Q18 as the peak of recent Pharma growth and expect a mirror image of 2017 for the remainder of the year, whereby growth will moderate significantly into 2H2018: Our forecast calls for Pharma operational growth of +9.2%/ 6.3%/ 5.1%/ 4.3% during 1Q – 4Q2018, and we now explicitly include the approval of apalutamide within our forecasts (drug model inside report).   Remicade erosion starting to become impactful and deteriorating pricing is likely affecting overall company gross margins: Mgmt noted that volumes for Remicade were generally steady during 4Q17, but this has come at the expense of pricing declines, which is a pure hit to product margins. Our best estimate is that the price erosion of Remicade negatively impacted overall company gross margins by – 30bps YoY during 4Q17." (1/24/2018)

Are investors shorting Johnson & Johnson?

Johnson & Johnson saw a increase in short interest in the month of March. As of March 15th, there was short interest totalling 20,596,959 shares, an increase of 23.2% from the February 28th total of 16,711,741 shares. Based on an average trading volume of 6,824,158 shares, the short-interest ratio is currently 3.0 days. Approximately 0.8% of the company's shares are short sold.

Who are some of Johnson & Johnson's key competitors?

Who are Johnson & Johnson's key executives?

Johnson & Johnson's management team includes the folowing people:
  • Mr. Alex Gorsky, Chairman & CEO (Age 58)
  • Mr. Dominic J. Caruso, Exec. VP & CFO (Age 60)
  • Dr. Paulus A. Stoffels, Exec. VP & Chief Scientific Officer (Age 56)
  • Mr. Joaquin Duato, Exec. VP & Worldwide Chairman of Pharmaceuticals (Age 55)
  • Ms. Sandra E. Peterson, Exec. VP & Group Worldwide Chairman (Age 59)

Has Johnson & Johnson been receiving favorable news coverage?

News articles about JNJ stock have trended somewhat positive recently, according to Accern. Accern rates the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Johnson & Johnson earned a coverage optimism score of 0.07 on Accern's scale. They also gave news stories about the company an impact score of 47.22 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of Johnson & Johnson?

Shares of JNJ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Johnson & Johnson's stock price today?

One share of JNJ stock can currently be purchased for approximately $126.66.

How big of a company is Johnson & Johnson?

Johnson & Johnson has a market capitalization of $339.82 billion and generates $76.45 billion in revenue each year. The company earns $1.30 billion in net income (profit) each year or $7.30 on an earnings per share basis. Johnson & Johnson employs 134,000 workers across the globe.

How can I contact Johnson & Johnson?

Johnson & Johnson's mailing address is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. The company can be reached via phone at 732-524-0400.


MarketBeat Community Rating for Johnson & Johnson (JNJ)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  549 (Vote Outperform)
Underperform Votes:  660 (Vote Underperform)
Total Votes:  1,209
MarketBeat's community ratings are surveys of what our community members think about Johnson & Johnson and other stocks. Vote "Outperform" if you believe JNJ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JNJ will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Johnson & Johnson (NYSE:JNJ) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
20 Wall Street analysts have issued ratings and price targets for Johnson & Johnson in the last 12 months. Their average twelve-month price target is $143.7222, suggesting that the stock has a possible upside of 13.47%. The high price target for JNJ is $165.00 and the low price target for JNJ is $110.00. There are currently 4 sell ratings, 6 hold ratings and 10 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.302.212.262.35
Ratings Breakdown: 4 Sell Rating(s)
6 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
7 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
6 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
5 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $143.7222$145.6111$145.5556$143.7895
Price Target Upside: 13.47% upside14.31% upside0.62% upside0.98% upside

Johnson & Johnson (NYSE:JNJ) Consensus Price Target History

Price Target History for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/20/2018Credit Suisse GroupLower Price TargetOutperform -> Outperform$154.00 -> $151.00LowView Rating Details
4/18/2018Wells FargoReiterated RatingOutperform$160.00 -> $150.00HighView Rating Details
4/18/2018Stifel NicolausLower Price TargetHold -> Hold$145.00 -> $135.00HighView Rating Details
4/18/2018Leerink SwannReiterated RatingOutperform$175.00 -> $160.00HighView Rating Details
4/18/2018Deutsche BankReiterated RatingBuyHighView Rating Details
4/17/2018Goldman SachsSet Price TargetSell$134.00LowView Rating Details
4/13/2018Jefferies GroupSet Price TargetBuy$153.00LowView Rating Details
4/10/2018Morgan StanleyLower Price TargetEqual Weight -> Equal Weight$148.00 -> $143.00LowView Rating Details
2/27/2018CitigroupLower Price TargetNeutral -> Neutral$150.00 -> $146.00MediumView Rating Details
1/24/2018BTIG ResearchReiterated RatingSell$110.00LowView Rating Details
1/9/2018Royal Bank of CanadaReiterated RatingBuyLowView Rating Details
1/2/2018JPMorgan ChaseDowngradeOverweight -> NeutralLowView Rating Details
12/12/2017BMO Capital MarketsBoost Price TargetOutperform$161.00MediumView Rating Details
10/18/2017BarclaysBoost Price TargetEqual Weight$140.00 -> $148.00N/AView Rating Details
10/18/2017CowenReiterated RatingOutperform$147.00 -> $155.00N/AView Rating Details
10/18/2017ArgusBoost Price TargetBuy -> Positive$145.00 -> $165.00N/AView Rating Details
10/4/2017Piper JaffrayReiterated RatingHold$120.00LowView Rating Details
9/30/2017UBSReiterated RatingBuy$148.00LowView Rating Details
7/21/2017Alembic Global AdvisorsDowngradeNeutral -> UnderweightLowView Rating Details
7/21/2017Atlantic SecuritiesDowngradeNeutral -> Underweight$113.00LowView Rating Details
11/28/2016Bank of AmericaReiterated RatingHold$126.00N/AView Rating Details
10/23/2016Societe GeneraleReiterated RatingHold$116.00N/AView Rating Details
5/20/2016Raymond JamesReiterated RatingOutperform$120.00N/AView Rating Details
5/20/2016Standpoint ResearchInitiated CoverageSell$94.00N/AView Rating Details
(Data available from 4/23/2016 forward)

Earnings

Johnson & Johnson (NYSE:JNJ) Earnings History and Estimates Chart

Earnings by Quarter for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) Earnings Estimates

2018 EPS Consensus Estimate: $8.08
2019 EPS Consensus Estimate: $8.64
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$1.99$2.00$2.00
Q2 20181$2.06$2.06$2.06
Q3 20181$2.02$2.02$2.02
Q4 20181$2.00$2.00$2.00
Q1 20191$2.27$2.27$2.27
Q2 20191$2.17$2.17$2.17
Q3 20191$2.12$2.12$2.12
Q4 20191$2.08$2.08$2.08

Johnson & Johnson (NYSE JNJ) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/17/2018$2.06N/AView Earnings Details
4/17/2018Q1 2018$2.00$2.06$19.4975 billion$20.0090 billionViewN/AView Earnings Details
1/23/2018Q4 2017$1.72$1.74$20.0797 billion$20.1950 billionViewListenView Earnings Details
10/17/2017Q3 2017$1.80$1.90$19.2910 billion$19.65 billionViewN/AView Earnings Details
7/18/2017Q2 2017$1.79$1.83$18.9418 billion$18.8390 billionViewN/AView Earnings Details
4/18/2017Q1 17$1.77$1.83$18.0198 billion$17.7660 billionViewN/AView Earnings Details
1/24/2017Q416$1.56$1.58$18.28 billion$18.10 billionViewN/AView Earnings Details
10/18/2016Q316$1.65$1.68$17.71 billion$17.80 billionViewListenView Earnings Details
7/19/2016Q216$1.68$1.74$17.98 billion$18.50 billionViewListenView Earnings Details
4/19/2016Q116$1.65$1.68$17.50 billion$17.50 billionViewListenView Earnings Details
1/26/2016Q415$1.42$1.44$17.88 billion$17.80 billionViewListenView Earnings Details
10/13/2015Q315$1.45$1.49$17.47 billion$17.10 billionViewListenView Earnings Details
7/14/2015Q215$1.69$1.71$17.76 billion$17.80 billionViewListenView Earnings Details
4/14/2015Q115$1.54$1.56$17.3077 billion$17.3740 billionViewListenView Earnings Details
1/20/2015Q414$1.25$1.27$18.59 billion$18.30 billionViewListenView Earnings Details
10/14/2014Q314$1.42$1.50$18.4139 billion$18.50 billionViewListenView Earnings Details
7/15/2014Q214$1.54$1.66$18.86 billion$19.50 billionViewN/AView Earnings Details
4/15/2014Q114$1.48$1.54$18.00 billion$18.10 billionViewN/AView Earnings Details
1/21/2014Q413$1.20$1.24$17.95 billion$18.40 billionViewN/AView Earnings Details
10/15/2013Q313$1.32$1.36$17.46 billion$17.60 billionViewN/AView Earnings Details
7/16/2013Q2 2013$1.39$1.48$17.71 billion$17.90 billionViewN/AView Earnings Details
4/16/2013Q1 2013$1.41$1.44$17.46 billion$17.50 billionViewN/AView Earnings Details
1/22/2013Q4 2012$1.17$1.19$17.67 billion$17.60 billionViewN/AView Earnings Details
10/16/2012$1.21$1.25ViewN/AView Earnings Details
7/17/2012$1.29$1.30ViewN/AView Earnings Details
4/17/2012$1.34$1.37ViewN/AView Earnings Details
1/24/2012$1.09$1.13ViewN/AView Earnings Details
10/18/2011$1.21$1.24ViewN/AView Earnings Details
7/19/2011$1.24$1.28ViewN/AView Earnings Details
4/19/2011$1.26$1.35ViewN/AView Earnings Details
1/25/2011$1.03$1.03ViewN/AView Earnings Details
10/19/2010Q3 2010$1.15$1.23ViewN/AView Earnings Details
7/20/2010Q2 2010$1.21$1.21ViewN/AView Earnings Details
4/20/2010Q1 2010$1.27$1.29ViewN/AView Earnings Details
1/26/2010Q4 2009$0.97$1.02ViewN/AView Earnings Details
10/13/2009Q3 2009$1.13$1.20ViewN/AView Earnings Details
7/14/2009Q2 2009$1.12$1.15ViewN/AView Earnings Details
4/14/2009Q1 2009$1.21$1.26ViewN/AView Earnings Details
1/20/2009Q4 2008$0.92$0.94ViewN/AView Earnings Details
10/14/2008Q3 2008$1.11$1.17ViewN/AView Earnings Details
7/15/2008Q2 2008$1.13$1.18ViewN/AView Earnings Details
4/15/2008Q1 2008$1.20$1.26ViewN/AView Earnings Details
1/22/2008Q4 2007$0.86$0.88ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Johnson & Johnson (NYSE:JNJ) Dividend Information

Johnson & Johnson pays an annual dividend of $3.36 per share, with a dividend yield of 2.65%. JNJ's most recent quarterly dividend payment was Tuesday, March 13. The company has grown its dividend for the last 55 consecutive years and is increasing its dividend by an average of 6.40% each year. Johnson & Johnson pays out 46.03% of its earnings out as a dividend.
Most Recent Dividend:3/13/2018
Annual Dividend:$3.36
Dividend Yield:2.65%
Dividend Growth:6.40% (3 Year Average)
Payout Ratio:46.03% (Trailing 12 Months of Earnings)
41.33% (Based on This Year's Estimates)
38.84% (Based on Next Year's Estimates)
Track Record:55 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/2/2018quarterly$0.842.39%2/26/20182/27/20183/13/2018
10/19/2017quarterly$0.842.37%11/27/201711/28/201712/12/2017
7/17/2017quarterly$0.842.5%8/25/20178/29/20179/12/2017
4/27/2017quarterly$0.842.72%5/25/20175/30/20176/13/2017
1/3/2017quarterly$0.802.77%2/24/20172/28/20173/14/2017
10/20/2016quarterly$0.8011/18/201611/22/201612/6/2016
7/18/2016quarterly$0.808/19/20168/23/20169/6/2016
4/28/2016quarterly$0.805/20/20165/24/20166/7/2016
1/4/2016quarterly$0.752/19/20162/23/20163/8/2016
10/22/2015quarterly$0.7511/20/201511/24/201512/8/2015
7/20/2015quarterly$0.758/21/20158/25/20159/8/2015
4/23/2015quarterly$0.752.97%5/21/20155/26/20156/9/2015
1/5/2015quarterly$0.702.71%2/20/20152/24/20153/10/2015
10/16/2014quarterly$0.702.89%11/21/201411/25/201412/9/2014
7/21/2014quarterly$0.702.73%8/22/20148/26/20149/9/2014
4/24/2014quarterly$0.702.81%5/22/20145/27/20146/10/2014
1/2/2014quarterly$0.662.87%2/21/20142/25/20143/11/2014
10/17/2013quarterly$0.662.88%11/22/201311/26/201312/10/2013
7/15/2013quarterly$0.662.92%8/23/20138/27/20139/10/2013
4/25/2013quarterly$0.663.1%5/23/20135/28/20136/11/2013
1/2/2013quarterly$0.613.45%2/22/20132/26/20133/12/2013
(Data available from 1/1/2013 forward)

Insider Trades

Johnson & Johnson (NYSE JNJ) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.22%
Institutional Ownership Percentage: 67.18%
Insider Trading History for Johnson & Johnson (NYSE:JNJ)
Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE JNJ) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/15/2018Paulus StoffelsVPSell155,342$129.86$20,172,712.12357,906View SEC Filing  
7/24/2017Paulus StoffelsVPSell102,692$133.14$13,672,412.88230,342View SEC Filing  
7/20/2017Dominic J CarusoVPSell82,591$136.72$11,291,841.52226,693View SEC Filing  
2/15/2017Paulus StoffelsVPSell22,000$117.29$2,580,380.00127,650View SEC Filing  
10/21/2016Charles PrinceDirectorBuy875$114.11$99,846.2526,520View SEC Filing  
7/26/2016Dominic J CarusoVPSell41,146$125.01$5,143,661.46157,819View SEC Filing  
7/22/2016Ronald A KapustaCAOSell2,935$125.01$366,904.3528,660View SEC Filing  
6/7/2016Gary J PrudenVPSell9,735$116.03$1,129,552.0543,630View SEC Filing  
6/7/2016Ronald A KapustaCAOSell3,000$115.79$347,370.0028,725View SEC Filing  
5/10/2016Ronald A KapustaCAOSell3,957$114.77$454,144.8929,682View SEC Filing  
2/17/2016Paulus StoffelsinsiderSell125,000$102.43$12,803,750.00122,543View SEC Filing  
2/3/2016Peter FasoloVPSell151,385$104.12$15,762,206.2037,735View SEC Filing  
10/23/2015Ronald A. KapustaCAOSell6,239$99.68$621,903.5220,803View SEC Filing  
6/2/2015Charles PrinceDirectorBuy2,500$99.22$248,050.00View SEC Filing  
4/28/2015Paulus StoffelsInsiderSell187,250$100.73$18,861,692.50View SEC Filing  
9/10/2014James CullenDirectorSell2,446$104.12$254,677.52View SEC Filing  
5/5/2014Stephen CosgroveInsiderSell22,000$100.05$2,201,100.0090,294View SEC Filing  
3/14/2014Peter FasoloVPSell6,824$93.15$635,655.6015,647View SEC Filing  
8/14/2013Stephen CosgroveInsiderSell17,200$91.39$1,571,908.0088,159View SEC Filing  
8/5/2013Michael UllmannVPSell16,140$93.68$1,511,995.2055,427View SEC Filing  
7/25/2013Paulus StoffelsInsiderSell45,440$92.40$4,198,656.00View SEC Filing  
7/18/2013Dominic J CarusoCFOSell30,000$90.31$2,709,300.00View SEC Filing  
11/12/2012James CullenDirectorSell13,900$69.70$968,830.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Johnson & Johnson (NYSE JNJ) News Headlines

Source:
DateHeadline
Johnson & Johnsons First-Quarter 2018 Earnings ReviewJohnson & Johnson's First-Quarter 2018 Earnings Review
www.fool.com - April 22 at 6:41 PM
[$$] Square, eBay, and the Future of Money[$$] Square, eBay, and the Future of Money
finance.yahoo.com - April 21 at 8:09 AM
IBM, Johnson & Johnson Weigh on the Dow WednesdayIBM, Johnson & Johnson Weigh on the Dow Wednesday
www.msn.com - April 20 at 5:31 PM
Johnson & Johnson (JNJ) PT Lowered to $151.00Johnson & Johnson (JNJ) PT Lowered to $151.00
www.americanbankingnews.com - April 20 at 11:39 AM
Johnson & Johnson is betting on vision care and expanding beyond contactsJohnson & Johnson is betting on vision care and expanding beyond contacts
finance.yahoo.com - April 20 at 8:11 AM
Q3 2018 EPS Estimates for Johnson & Johnson (JNJ) Increased by AnalystQ3 2018 EPS Estimates for Johnson & Johnson (JNJ) Increased by Analyst
www.americanbankingnews.com - April 20 at 8:04 AM
Johnson & Johnson: Steady As She GoesJohnson & Johnson: Steady As She Goes
seekingalpha.com - April 19 at 5:51 PM
Healthcare ETFs in Focus After Johnson & Johnson Q1 EarningsHealthcare ETFs in Focus After Johnson & Johnson Q1 Earnings
finance.yahoo.com - April 19 at 5:51 PM
Johnson & Johnson (JNJ) Lowered to "Hold" at BidaskClubJohnson & Johnson (JNJ) Lowered to "Hold" at BidaskClub
www.americanbankingnews.com - April 19 at 9:04 AM
Johnson & Johnson (JNJ) Q1 2018 Results - Earnings Call TranscriptJohnson & Johnson (JNJ) Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - April 19 at 8:05 AM
Location revealed: Johnson & Johnson institutes new HQ to go in Lake Nonas Medical CityLocation revealed: Johnson & Johnson institute's new HQ to go in Lake Nona's Medical City
www.bizjournals.com - April 19 at 8:05 AM
Kentucky Gov. Matt Bevin slams state AG's lawsuit against J&J: 'These are political moves'Kentucky Gov. Matt Bevin slams state AG's lawsuit against J&J: 'These are political moves'
finance.yahoo.com - April 19 at 8:05 AM
After the Bell: Dow Drops 38 Points Because…IBMAfter the Bell: Dow Drops 38 Points Because…IBM
finance.yahoo.com - April 19 at 8:05 AM
3 Drugs That Are Moving the Needle at Johnson & Johnson3 Drugs That Are Moving the Needle at Johnson & Johnson
finance.yahoo.com - April 19 at 8:05 AM
FY2018 Earnings Forecast for Johnson & Johnson (JNJ) Issued By Leerink SwannFY2018 Earnings Forecast for Johnson & Johnson (JNJ) Issued By Leerink Swann
www.americanbankingnews.com - April 19 at 7:17 AM
Royal Bank of Canada Reiterates Buy Rating for Johnson & Johnson (JNJ)Royal Bank of Canada Reiterates Buy Rating for Johnson & Johnson (JNJ)
www.americanbankingnews.com - April 19 at 12:28 AM
Johnson & Johnson: Good Start Of The Year But Valuation Is Still Not Cheap EnoughJohnson & Johnson: Good Start Of The Year But Valuation Is Still Not Cheap Enough
seekingalpha.com - April 18 at 5:54 PM
Kentucky Governor Bevin: I'm not on board with JNJ opioid...Kentucky Governor Bevin: I'm not on board with JNJ opioid...
finance.yahoo.com - April 18 at 5:54 PM
Kentucky Gov. Matt Bevin slams state AGs lawsuit against J&J: These are political movesKentucky Gov. Matt Bevin slams state AG's lawsuit against J&J: 'These are political moves'
finance.yahoo.com - April 18 at 5:54 PM
Kentucky accuses J&J of contributing to opioid epidemicKentucky accuses J&J of contributing to opioid epidemic
www.cnbc.com - April 18 at 1:34 PM
Johnson & Johnson (JNJ) PT Lowered to $135.00Johnson & Johnson (JNJ) PT Lowered to $135.00
www.americanbankingnews.com - April 18 at 10:10 AM
Johnson & Johnson (JNJ) Receives Outperform Rating from Wells FargoJohnson & Johnson (JNJ) Receives Outperform Rating from Wells Fargo
www.americanbankingnews.com - April 18 at 10:06 AM
Johnson & Johnsons (JNJ) Outperform Rating Reiterated at Leerink SwannJohnson & Johnson's (JNJ) Outperform Rating Reiterated at Leerink Swann
www.americanbankingnews.com - April 18 at 9:50 AM
Johnson & Johnson (JNJ) Given a $154.00 Price Target by Credit Suisse Group AnalystsJohnson & Johnson (JNJ) Given a $154.00 Price Target by Credit Suisse Group Analysts
www.americanbankingnews.com - April 18 at 8:47 AM
Johnson & Johnson (JNJ) Earns "Buy" Rating from Deutsche BankJohnson & Johnson (JNJ) Earns "Buy" Rating from Deutsche Bank
www.americanbankingnews.com - April 18 at 8:41 AM
Johnson & Johnson 2018 Q1 - Results - Earnings Call SlidesJohnson & Johnson 2018 Q1 - Results - Earnings Call Slides
seekingalpha.com - April 18 at 8:06 AM
Johnson & Johnsons stock gains after profit and revenue beat, raised outlookJohnson & Johnson's stock gains after profit and revenue beat, raised outlook
www.marketwatch.com - April 18 at 8:06 AM
Johnson & Johnson CFO: Pharma business continues stellar resultsJohnson & Johnson CFO: Pharma business continues 'stellar' results
www.cnbc.com - April 18 at 8:06 AM
The resume of the future will tell employers who you are, and not just what you’ve doneThe resume of the future will tell employers who you are, and not just what you’ve done
finance.yahoo.com - April 18 at 8:06 AM
Johnson & Johnson: 1Q Earnings SnapshotJohnson & Johnson: 1Q Earnings Snapshot
www.cnbc.com - April 17 at 6:07 PM
Johnson & Johnsons (JNJ) Management on Q1 2018 Results - Earnings Call TranscriptJohnson & Johnson's (JNJ) Management on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - April 17 at 6:07 PM
J&J raises sales forecast on strong demand for cancer drugsJ&J raises sales forecast on strong demand for cancer drugs
www.reuters.com - April 17 at 6:07 PM
Why Johnson & Johnson’s (NYSE:JNJ) ROE Of 2.16% Does Not Tell The Whole StoryWhy Johnson & Johnson’s (NYSE:JNJ) ROE Of 2.16% Does Not Tell The Whole Story
finance.yahoo.com - April 17 at 6:07 PM
Johnson & Johnson Stock Dips Despite Q1 Earnings BeatJohnson & Johnson Stock Dips Despite Q1 Earnings Beat
investorplace.com - April 17 at 1:20 PM
Johnson & Johnson Stock Dips Despite Q1 Earnings BeatJohnson & Johnson Stock Dips Despite Q1 Earnings Beat
investorplace.com - April 17 at 1:01 PM
Goldman Sachs Analysts Give Johnson & Johnson (JNJ) a $134.00 Price TargetGoldman Sachs Analysts Give Johnson & Johnson (JNJ) a $134.00 Price Target
www.americanbankingnews.com - April 17 at 12:19 PM
Johnson & Johnson tops 1Q views on sales spike, but net dipsJohnson & Johnson tops 1Q views on sales spike, but net dips
marketbeat.com - April 17 at 10:55 AM
Johnson & Johnson (JNJ) Updates FY18 Earnings GuidanceJohnson & Johnson (JNJ) Updates FY18 Earnings Guidance
www.americanbankingnews.com - April 17 at 9:14 AM
Johnson & Johnson (JNJ) Releases  Earnings Results, Beats Expectations By $0.05 EPSJohnson & Johnson (JNJ) Releases Earnings Results, Beats Expectations By $0.05 EPS
www.americanbankingnews.com - April 17 at 8:31 AM
Heres what to expect from Johnson & Johnson earningsHere's what to expect from Johnson & Johnson earnings
finance.yahoo.com - April 17 at 8:13 AM
Johnson & Johnson tops profit and revenue expectations in 1QJohnson & Johnson tops profit and revenue expectations in 1Q
www.cnbc.com - April 17 at 8:13 AM
Johnson & Johnson beats by $0.05, beats on revenueJohnson & Johnson beats by $0.05, beats on revenue
seekingalpha.com - April 17 at 8:13 AM
Johnson & Johnson: Is Zytiga Patent Loss Priced In?Johnson & Johnson: Is Zytiga Patent Loss Priced In?
seekingalpha.com - April 17 at 8:13 AM
J&J (JNJ) Beats on Q1 Earnings & Sales, Ups 2018 Sales ViewJ&J (JNJ) Beats on Q1 Earnings & Sales, Ups 2018 Sales View
www.zacks.com - April 17 at 8:13 AM
Global stocks turn higher on upbeat corporate earningsGlobal stocks turn higher on upbeat corporate earnings
finance.yahoo.com - April 17 at 8:13 AM
[$$] Johnson & Johnson Raises Sales Outlook[$$] Johnson & Johnson Raises Sales Outlook
finance.yahoo.com - April 17 at 8:13 AM
Dominic Caruso Says Johnson & Johnson Is Still Planning for Strong 2018Dominic Caruso Says Johnson & Johnson Is Still Planning for Strong 2018
finance.yahoo.com - April 17 at 8:13 AM
Johnson & Johnson CFO Plans for a Strong Year for 2018Johnson & Johnson CFO Plans for a Strong Year for 2018
finance.yahoo.com - April 17 at 8:13 AM
Stocks making the biggest moves premarket: UNH, JNJ, GS, NFLX, ROKU, DIS & moreStocks making the biggest moves premarket: UNH, JNJ, GS, NFLX, ROKU, DIS & more
finance.yahoo.com - April 17 at 8:13 AM
Pharma fuels Johnson & Johnsons first-quarter earnings beatPharma fuels Johnson & Johnson's first-quarter earnings beat
www.cnbc.com - April 17 at 7:13 AM

SEC Filings

Johnson & Johnson (NYSE:JNJ) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Johnson & Johnson (NYSE:JNJ) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Johnson & Johnson (NYSE JNJ) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.